238 related articles for article (PubMed ID: 37831776)
1. Coinhibition of topoisomerase 1 and BRD4-mediated pause release selectively kills pancreatic cancer via readthrough transcription.
Cameron DP; Grosser J; Ladigan S; Kuzin V; Iliopoulou E; Wiegard A; Benredjem H; Jackson K; Liffers ST; Lueong S; Cheung PF; Vangala D; Pohl M; Viebahn R; Teschendorf C; Wolters H; Usta S; Geng K; Kutter C; Arsenian-Henriksson M; Siveke JT; Tannapfel A; Schmiegel W; Hahn SA; Baranello L
Sci Adv; 2023 Oct; 9(41):eadg5109. PubMed ID: 37831776
[TBL] [Abstract][Full Text] [Related]
2. A BRD4-mediated elongation control point primes transcribing RNA polymerase II for 3'-processing and termination.
Arnold M; Bressin A; Jasnovidova O; Meierhofer D; Mayer A
Mol Cell; 2021 Sep; 81(17):3589-3603.e13. PubMed ID: 34324863
[TBL] [Abstract][Full Text] [Related]
3. Chromatin remodeller SMARCA4 recruits topoisomerase 1 and suppresses transcription-associated genomic instability.
Husain A; Begum NA; Taniguchi T; Taniguchi H; Kobayashi M; Honjo T
Nat Commun; 2016 Feb; 7():10549. PubMed ID: 26842758
[TBL] [Abstract][Full Text] [Related]
4. RNA Polymerase II Regulates Topoisomerase 1 Activity to Favor Efficient Transcription.
Baranello L; Wojtowicz D; Cui K; Devaiah BN; Chung HJ; Chan-Salis KY; Guha R; Wilson K; Zhang X; Zhang H; Piotrowski J; Thomas CJ; Singer DS; Pugh BF; Pommier Y; Przytycka TM; Kouzine F; Lewis BA; Zhao K; Levens D
Cell; 2016 Apr; 165(2):357-71. PubMed ID: 27058666
[TBL] [Abstract][Full Text] [Related]
5. The KRAS-regulated kinome identifies WEE1 and ERK coinhibition as a potential therapeutic strategy in KRAS-mutant pancreatic cancer.
Diehl JN; Klomp JE; Snare KR; Hibshman PS; Blake DR; Kaiser ZD; Gilbert TSK; Baldelli E; Pierobon M; Papke B; Yang R; Hodge RG; Rashid NU; Petricoin EF; Herring LE; Graves LM; Cox AD; Der CJ
J Biol Chem; 2021 Nov; 297(5):101335. PubMed ID: 34688654
[TBL] [Abstract][Full Text] [Related]
6. Nanoformulation of BRD4-Degrading PROTAC: Improving Druggability To Target the 'Undruggable' MYC in Pancreatic Cancer.
Minko T
Trends Pharmacol Sci; 2020 Oct; 41(10):684-686. PubMed ID: 32893006
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of BRD4 suppresses tumor growth in prostate cancer via the enhancement of FOXO1 expression.
Tan Y; Wang L; Du Y; Liu X; Chen Z; Weng X; Guo J; Chen H; Wang M; Wang X
Int J Oncol; 2018 Dec; 53(6):2503-2517. PubMed ID: 30272279
[TBL] [Abstract][Full Text] [Related]
8. SOX9 activity is induced by oncogenic Kras to affect MDC1 and MCMs expression in pancreatic cancer.
Zhou H; Qin Y; Ji S; Ling J; Fu J; Zhuang Z; Fan X; Song L; Yu X; Chiao PJ
Oncogene; 2018 Feb; 37(7):912-923. PubMed ID: 29059173
[TBL] [Abstract][Full Text] [Related]
9. Co-targeting BET bromodomain BRD4 and RAC1 suppresses growth, stemness and tumorigenesis by disrupting the c-MYC-G9a-FTH1axis and downregulating HDAC1 in molecular subtypes of breast cancer.
Ali A; Shafarin J; Unnikannan H; Al-Jabi N; Jabal RA; Bajbouj K; Muhammad JS; Hamad M
Int J Biol Sci; 2021; 17(15):4474-4492. PubMed ID: 34803511
[TBL] [Abstract][Full Text] [Related]
10. BET inhibitors block pancreatic stellate cell collagen I production and attenuate fibrosis in vivo.
Kumar K; DeCant BT; Grippo PJ; Hwang RF; Bentrem DJ; Ebine K; Munshi HG
JCI Insight; 2017 Feb; 2(3):e88032. PubMed ID: 28194432
[TBL] [Abstract][Full Text] [Related]
11. BRD4 promotes gastric cancer progression through the transcriptional and epigenetic regulation of c-MYC.
Ba M; Long H; Yan Z; Wang S; Wu Y; Tu Y; Gong Y; Cui S
J Cell Biochem; 2018 Jan; 119(1):973-982. PubMed ID: 28681984
[TBL] [Abstract][Full Text] [Related]
12. Distinct layers of BRD4-PTEFb reveal bromodomain-independent function in transcriptional regulation.
Zheng B; Gold S; Iwanaszko M; Howard BC; Wang L; Shilatifard A
Mol Cell; 2023 Aug; 83(16):2896-2910.e4. PubMed ID: 37442129
[TBL] [Abstract][Full Text] [Related]
13. An oncogenic KRAS transcription program activates the RHOGEF ARHGEF2 to mediate transformed phenotypes in pancreatic cancer.
Kent OA; Sandí MJ; Burston HE; Brown KR; Rottapel R
Oncotarget; 2017 Jan; 8(3):4484-4500. PubMed ID: 27835861
[TBL] [Abstract][Full Text] [Related]
14. Cdc6 as a novel target in cancer: Oncogenic potential, senescence and subcellular localisation.
Lim N; Townsend PA
Int J Cancer; 2020 Sep; 147(6):1528-1534. PubMed ID: 32010971
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylase class-I inhibition promotes epithelial gene expression in pancreatic cancer cells in a BRD4- and MYC-dependent manner.
Mishra VK; Wegwitz F; Kosinsky RL; Sen M; Baumgartner R; Wulff T; Siveke JT; Schildhaus HU; Najafova Z; Kari V; Kohlhof H; Hessmann E; Johnsen SA
Nucleic Acids Res; 2017 Jun; 45(11):6334-6349. PubMed ID: 28369619
[TBL] [Abstract][Full Text] [Related]
16. MYC activity at enhancers drives prognostic transcriptional programs through an epigenetic switch.
Jakobsen ST; Jensen RAM; Madsen MS; Ravnsborg T; Vaagenso CS; Siersbæk MS; Einarsson H; Andersson R; Jensen ON; Siersbæk R
Nat Genet; 2024 Apr; 56(4):663-674. PubMed ID: 38454021
[TBL] [Abstract][Full Text] [Related]
17. BRD4 coordinates recruitment of pause release factor P-TEFb and the pausing complex NELF/DSIF to regulate transcription elongation of interferon-stimulated genes.
Patel MC; Debrosse M; Smith M; Dey A; Huynh W; Sarai N; Heightman TD; Tamura T; Ozato K
Mol Cell Biol; 2013 Jun; 33(12):2497-507. PubMed ID: 23589332
[TBL] [Abstract][Full Text] [Related]
18. Compensatory RNA polymerase 2 loading determines the efficacy and transcriptional selectivity of JQ1 in Myc-driven tumors.
Donato E; Croci O; Sabò A; Muller H; Morelli MJ; Pelizzola M; Campaner S
Leukemia; 2017 Feb; 31(2):479-490. PubMed ID: 27443262
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer.
Shimamura T; Chen Z; Soucheray M; Carretero J; Kikuchi E; Tchaicha JH; Gao Y; Cheng KA; Cohoon TJ; Qi J; Akbay E; Kimmelman AC; Kung AL; Bradner JE; Wong KK
Clin Cancer Res; 2013 Nov; 19(22):6183-92. PubMed ID: 24045185
[TBL] [Abstract][Full Text] [Related]
20. BRD4 inhibition induces synthetic lethality in ARID2-deficient hepatocellular carcinoma by increasing DNA damage.
He DD; Shang XY; Wang N; Wang GX; He KY; Wang L; Han ZG
Oncogene; 2022 Mar; 41(10):1397-1409. PubMed ID: 35017665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
